<DOC>
	<DOCNO>NCT00411333</DOCNO>
	<brief_summary>The retinal vasculature change dramatically patient diabetic retinopathy especially non-proliferative proliferative disease . The retinal vasculature image quantified use special dye . This study test whether pattern retinal vasculature change patient different level diabetic retinopathy quantify use computerized image analysis . In addition , study evaluate whether new drug treat diabetic retinopathy able reverse vascular change .</brief_summary>
	<brief_title>Vascular Remodeling Effects Angiogenic Inhibition Diabetic Retinopathy</brief_title>
	<detailed_description>In study , study whether vascular density decrease diabetic retinopathy prior pathological neovascularization see proliferative disease result blindness 50 percent patient , whether adverse , early vascular remodel neovascularization reverse anti-angiogenic therapeutic . We show vascular density decrease early stage diabetic retinopathy , prior pathological neovascularization defines proliferative retinopathy , change may reversible new anti-angiogenic therapeutic . To test hypothesis determine ( 1 ) blood vessel remodel whether vascular density truly decrease diabetic retinopathy ( 2 ) anti-angiogenic steroid triamcinolone acetonide affect vascular density pattern human diabetic retinopathy experimental model , avian CAM model . Twenty patient ( n = 20 ) 4 NPDR stage enrol . In addition , control group 20 normal subject recruit clinical practice diabetes evidence vascular disease , total 100 patient clinical trial .</detailed_description>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Vascular Remodeling</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>Presence mild , moderate , severe , severe nonproliferative diabetic retinopathy ( defined ETDRS level &gt; 10 ) least one eye ( base ETDRS criterion ) Any condition might impair patient 's ability give inform consent Any condition medium opacity might impair patient 's ability perform vision test , color fundus photograph fluorescein angiography Severe allergy contraindication sodium fluorescein dye Participating ophthalmic clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>diabetic retinopathy</keyword>
	<keyword>fluorescein angiography</keyword>
	<keyword>steroid</keyword>
	<keyword>anti-angiogenesis</keyword>
</DOC>